Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI ultrasound could replace costly MRI for Kids' fatty liver

NCT ID NCT07265011

Diagnosis Sponsor: Jae Won Choi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an artificial intelligence (AI) program can accurately measure liver fat using regular ultrasound images in children aged 8 to 18 with fatty liver disease. The AI's results were compared to MRI scans, which are the current gold standard. The goal is to provide a simpler, cheaper, and more accessible way to diagnose and monitor liver fat without needing an MRI.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Dec 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * participants aged 8 to 18 years clinically indicated for liver ultrasound examination to evaluate hepatic steatosis * participants with suspected or known metabolic dysfunction-associated steatotic liver disease (MASLD) * able to understand the study purpose and provide written informed consent (from both participant and legal guardian). * agree to undergo same-day liver MRI examination in addition to the ultrasound Exclusion Criteria: * unable to cooperate with imaging procedures * parent or legal guardian unable to understand the study explanation * contraindications to MRI * determined by the investigator to be otherwise unsuitable for participation after consultation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASLD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASLD Pediatric

Contacts and locations

Locations

  • Seoul National University Hospital

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.